Oklo wins NRC license as it pushes toward 2028 commercial nuclear power
Oklo’s stock wavered after earnings, but the Santa Clara-based startup scored a key win when its Atomic Alchemy subsidiary secured the Nuclear Regulatory Commission license to handle, process, and distribute isotopes, creating a new revenue stream even as its advanced fast reactors await NRC approval and the company remains pre‑revenue. 2025 net loss rose to $105.7 million on $139.2 million in operating expenses, with $1.4 billion in cash and equivalents, and management signaled ongoing losses and higher investing outlays. Positive developments include a Department of Energy agreement to support its first reactor at Idaho National Laboratory and a Meta Platforms partnership to build a nuclear campus in Ohio, underscoring progress toward Oklo’s goal of commercially deploying power around 2028 despite regulatory and funding uncertainties.
